We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-25.4%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.39B
AUM Growth
-$1.3B
Cap. Flow
-$296M
Cap. Flow %
-12.4%
Top 10 Hldgs %
47.64%
Holding
157
New
7
Increased
9
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$25.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$20.3M
3
VIGL
Vigil Neuroscience
VIGL
+$14.8M
4
IGMS
IGM Biosciences
IGMS
+$9.31M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.83M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$18.8M
2
NG icon
NovaGold Resources
NG
+$17.8M
3
ALBO
Albireo Pharma Inc
ALBO
+$14M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$12.7M
5
KRYS icon
Krystal Biotech
KRYS
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 90.67%
2 Consumer Discretionary 6.64%
3 Financials 0.85%
4 Consumer Staples 0.31%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRIS icon
101
Curis
CRIS
$9.67M
$3.09M 0.13%
3,250
– –
GRTS
102
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$3.09M 0.13%
750,000
– –
CYCN icon
103
Cyclerion Therapeutics
CYCN
$14.9M
$3.08M 0.13%
138,956
– –
ZYME icon
104
Zymeworks
ZYME
$1.63B
$2.95M 0.12%
450,000
– –
IMMP
105
Immutep
IMMP
$56.8M
$2.74M 0.11%
1,000,000
– –
CGEM icon
106
Cullinan Oncology
CGEM
$1.04B
$2.62M 0.11%
250,000
– –
YI
107
111 Inc
YI
$33.4M
$2.57M 0.11%
96,635
– –
BBIO icon
108
BridgeBio Pharma
BBIO
$16.6B
$2.54M 0.11%
250,000
– –
ME
109
DELISTED
23andMe Holding Co
ME
$2.53M 0.11%
33,050
– –
ARAV
110
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.53M 0.11%
1,311,291
– –
ORIC icon
111
Oric Pharmaceuticals
ORIC
$1.16B
$2.14M 0.09%
400,000
– –
TCRR
112
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.07M 0.09%
750,000
– –
WVE icon
113
Wave Life Sciences
WVE
$1.12B
$2M 0.08%
1,000,000
– –
CRDF icon
114
Cardiff Oncology
CRDF
$60.9M
$1.86M 0.08%
750,000
– –
AXLA
115
DELISTED
Axcella Health Inc. Common Stock
AXLA
$1.83M 0.08%
28,500
– –
MREO
116
Mereo BioPharma
MREO
$50.7M
$1.68M 0.07%
1,500,000
– –
KNTE
117
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.41M 0.06%
125,000
– –
IRWD icon
118
Ironwood Pharmaceuticals
IRWD
$604M
$1.39M 0.06%
110,532
– –
ORTX
119
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.28M 0.05%
180,386
– –
CDAK
120
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$1.25M 0.05%
200,000
– –
HIPO icon
121
Hippo Holdings
HIPO
$772M
$1.19M 0.05%
24,000
– –
OLMA icon
122
Olema Pharmaceuticals
OLMA
$991M
$1.11M 0.05%
260,500
– –
XP icon
123
XP
XP
$8.45B
$1.05M 0.04%
+35,000
New +$1.09M
CRBU icon
124
Caribou Biosciences
CRBU
$147M
$967K 0.04%
105,347
-300,000
-74% -$3.16M
AMLX icon
125
Amylyx Pharmaceuticals
AMLX
$2.16B
$964K 0.04%
+75,000
New +$1.69M
3 4
5
6 7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2022 Portfolio in Review

As of Q1 2022, Artal Group held 157 positions worth $2.39B, down 35% from $3.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $296M in Q1 2022, closing 20 positions and reducing 11 holdings. Its most notable exit was NovaGold Resources, an estimated $17.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Vigil Neuroscience worth $7.88M.

  • Artal Group's largest Q1 2022 buy was Vigil Neuroscience: 1,121,191 shares worth $7.88M.
  • Artal Group added most to argenx in Q1 2022, an estimated $25.4M increase.
  • Artal Group's biggest Q1 2022 reduction was Amicus Therapeutics, cutting an estimated $18.8M.
  • Artal Group fully exited NovaGold Resources in Q1 2022, selling an estimated $17.8M.
  • Artal Group's ten largest holdings make up 48% of its $2.39B portfolio in Q1 2022.
  • Artal Group opened 7 new positions and closed 20 in Q1 2022.
  • Artal Group's portfolio value fell 35% quarter-over-quarter to $2.39B.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.